Fraser SyndromeNCT00032877
Genetic Analysis of Fraser Syndrome and Fryns Syndrome
An observational study of Fraser Syndrome and Fryns Syndrome, run by National Human Genome Research Institute (NHGRI) at 1 site in United States.
Trial summary
This study will examine blood or other tissue samples from patients with Fraser syndrome and patients with Fryns syndrome to try to identify the gene responsible for these diseases. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Fraser Syndrome, Fryns Syndrome, Chromosomal Abnormalities
- How many people
- 400 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2002to Feb 2003
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- For Fraser syndrome, clinical criteria for inclusion will be by:
- Satisfying diagnostic criteria for Fraser syndrome. These are at least two major criteria and one minor criterion (listed below) or one major criterion and four minor criteria.
- Major criteria:
- Cryptophthalmos
- Syndactyly
- Abnormal genitalia
Show all 22Show fewer
- Sib with cryptophthalmos syndrome
- Minor criteria:
- Congenital malformation of the nose
- Congenital malformations of the ears
- Congenital malformation of the larynx
- Cleft lip and/or palate
- Skeletal defects
- Umbilical hernia
- Renal agenesis
- Mental retardation
- Cryptophthalmos with additional anomalies consistent with the phenotypic spectrum of Fraser syndrome but without satisfying diagnotisic for Fraser syndrome may also be considered sufficient for inclusion.
- For Fryns syndrome, formal diagnostic criteria have not been published. The clinical criteria for inclusion will be:
- Diaphragmatic hernia with at least one additional anomaly found in the spectrum of Fryns syndrome, including cleft lip and or palate, renal or genital malformations, cerebral malformations or hydrocephalus, corneal clouding, craniofacial dysmorphism and brachydactyly or nail hypoplasia, pulmonary agenesis or microphthalmia.
- Patients with four or more of the additional anomalies may be included in the study.
- Parents and unaffected siblings will be also included for linkage analysis.
- Specimens of DNA or whole blood for DNA extraction collected outside the NIH may be accepted into the study if they are obtained through an approved NIH protocol consent form.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, 20892
About this study
Official title: Molecular Genetic Analysis of Fraser Syndrome and Fryns Syndrome
This study will examine blood or other tissue samples from patients with Fraser syndrome and patients with Fryns syndrome to try to identify the gene responsible for these diseases. Fraser syndrome is characterized by congenital abnormalities including cryptophthalmos (lack of eyelid formation), syndactyly (webbed fingers or toes) and abnormal genitalia. Patients may also have abnormalities of the nose, ears and larynx (voice box), cleft lip or palate, and kidney agenesis. Fryns syndrome is characterized by hernia through the diaphragm, cloudy cornea, coarse facial features, cleft lip or palate, abnormal fingers and toes, heart, kidney and brain malformations and hydrocephalus (accumulation of fluid around the brain). This protocol consists of laboratory study only; it does not involve patient care or patient counseling.
Patients with Fraser syndrome or Fryns syndrome are eligible for this study. Parents and healthy siblings of patients will also be included for genetic study, and parents of children with undiagnosed multiple congenital anomalies syndromes will be included for comparison study.
Participants will provide a blood sample (about 8 to 10 teaspoons from adults; 1 to 3 teaspoons from children) or sample of skin cells collected by swabbing the inner surface of the cheek. Some patients may undergo a skin biopsy, in which a small skin sample (about 1/8-inch in diameter) is surgically removed. The tissue samples will be used to obtain DNA (genetic material) for laboratory testing. A permanent cell line-a collection of cells grown in the laboratory from the original tissue specimen-will also be established to enable additional testing in the future.
Read the detailed description
We would like to determine the molecular genetic etiology of two rare human malformation syndromes, Fraser syndrome (OMIM 219000) and Fryns syndrome (OMIM 229850). To date, we are unaware of molecular genetic studies that have been performed in either syndrome.
We are planning to perform molecular genetic studies on DNA specimens from affected individuals ascertained outside NIH by other clinicians and/or reported in the medical literature. Should these studies prove fruitful, we would plan to expand this work to a combined clinical and molecular study to fully delineate the phenotypes associated with these disorders.
We plan to collect DNA specimens from affected patients and from unaffected siblings and parents and to evaluate the specimens in the laboratory by linkage analysis, physical mapping, candidate gene characterization and mutation screening. If the causative genes(s) for either syndrome are identified, then mouse models of the diseases may be developed and cell biologic studies of normal and mutant proteins may be undertaken.
The cloning of these genes would enable better characterization of human developmental processes and improve patient counseling for individuals and families affected by these diseases.
- Keywords
- Linkage Study, Gene Identification Study, Diaphragmatic Hernia, Fraser Syndrome, Cryptophthalmos, Fryns Syndrome, Hydrolethalus Syndrome, Positional Cloning
- Medical subject headings
- Fraser Syndrome, Fryns syndrome, Chromosome Aberrations, Abnormalities, Multiple, Hernia, Diaphragmatic, Hydrolethalus syndrome
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2002 (estimated)
- Study startApr 2002
- Study completionFeb 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Fraser SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 400 participants
Sponsor and investigators
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00032877
- Sponsor's protocol ID
- 020148
- Other IDs
- 02-HG-0148
- Status last verified
- Feb 2003
- First submitted
- 4 Apr 2002
- Last updated
- 4 Mar 2008
- Results posted
- No
Publications
Acosta JM, Chai Y, Meara JG, Bringas P Jr, Anderson KD, Warburton D. Prenatal exposure to nitrofen induces Fryns phenotype in mice. Ann Plast Surg. 2001 Jun;46(6):635-40. doi: 10.1097/00000637-200106000-00012.
PubMed 11405365Andiran F, Tanyel FC, Hicsonmez A. Fraser syndrome associated with anterior urethral atresia. Am J Med Genet. 1999 Feb 12;82(4):359-61. doi: 10.1002/(sici)1096-8628(19990212)82:43.0.co;2-q. No abstract available.
PubMed 10051174Balci S, Altinok G, Ozaltin F, Aktas D, Niron EA, Onol B. Laryngeal atresia presenting as fetal ascites, olygohydramnios and lung appearance mimicking cystic adenomatoid malformation in a 25-week-old fetus with Fraser syndrome. Prenat Diagn. 1999 Sep;19(9):856-58. doi: 10.1002/(sici)1097-0223(199909)19:93.0.co;2-x.
PubMed 10521845
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Genetic Analysis of Fraser Syndrome and Fryns Syndrome
- ClinicalTrials.gov ID
- NCT00032877
- Acronym / sponsor ID
- 020148
- Keywords
- Linkage Study, Gene Identification Study, Diaphragmatic Hernia, Fraser Syndrome, Cryptophthalmos, Fryns Syndrome, Hydrolethalus Syndrome, Positional Cloning
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants
- Lead sponsor
- National Human Genome Research Institute (NHGRI)US National Institutes of Health
- Study start
- Apr 2002
- Study completion
- Feb 2003
- First posted
- 5 Apr 2002 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine blood or other tissue samples from patients with Fraser syndrome and patients with Fryns syndrome to try to identify the gene responsible for these diseases. Fraser syndrome is characterized by congenital abnormalities including cryptophthalmos (lack of eyelid formation), syndactyly (webbed fingers or toes) and abnormal genitalia. Patients may also have abnormalities of the nose, ears and larynx (voice box), cleft lip or palate, and kidney agenesis. Fryns syndrome is characterized by hernia through the diaphragm, cloudy cornea, coarse facial features, cleft lip or palate, abnormal fingers and toes, heart, kidney and brain malformations and hydrocephalus (accumulation of fluid around the brain). This protocol consists of laboratory study only; it does not involve patient care or patient counseling.
Patients with Fraser syndrome or Fryns syndrome are eligible for this study. Parents and healthy siblings of patients will also be included for genetic study, and parents of children with undiagnosed multiple congenital anomalies syndromes will be included for comparison study.
Participants will provide a blood sample (about 8 to 10 teaspoons from adults; 1 to 3 teaspoons from children) or sample of skin cells collected by swabbing the inner surface of the cheek. Some patients may undergo a skin biopsy, in which a small skin sample (about 1/8-inch in diameter) is surgically removed. The tissue samples will be used to obtain DNA (genetic material) for laboratory testing. A permanent cell line-a collection of cells grown in the laboratory from the original tissue specimen-will also be established to enable additional testing in the future.
Detailed description
We would like to determine the molecular genetic etiology of two rare human malformation syndromes, Fraser syndrome (OMIM 219000) and Fryns syndrome (OMIM 229850). To date, we are unaware of molecular genetic studies that have been performed in either syndrome.
We are planning to perform molecular genetic studies on DNA specimens from affected individuals ascertained outside NIH by other clinicians and/or reported in the medical literature. Should these studies prove fruitful, we would plan to expand this work to a combined clinical and molecular study to fully delineate the phenotypes associated with these disorders.
We plan to collect DNA specimens from affected patients and from unaffected siblings and parents and to evaluate the specimens in the laboratory by linkage analysis, physical mapping, candidate gene characterization and mutation screening. If the causative genes(s) for either syndrome are identified, then mouse models of the diseases may be developed and cell biologic studies of normal and mutant proteins may be undertaken.
The cloning of these genes would enable better characterization of human developmental processes and improve patient counseling for individuals and families affected by these diseases.
Study design
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (22 listed)
- Satisfying diagnostic criteria for Fraser syndrome. These are at least two major criteria and one minor criterion (listed below) or one major criterion and four minor criteria.
- Cryptophthalmos
- Syndactyly
- Abnormal genitalia
- Sib with cryptophthalmos syndrome
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2008.
- Background: PubMed 11405365Acosta JM, Chai Y, Meara JG, Bringas P Jr, Anderson KD, Warburton D. Prenatal exposure to nitrofen induces Fryns phenotype in mice. Ann Plast Surg. 2001 Jun;46(6):635-40. doi: 10.1097/00000637-200106000-00012.
- Background: PubMed 10051174Andiran F, Tanyel FC, Hicsonmez A. Fraser syndrome associated with anterior urethral atresia. Am J Med Genet. 1999 Feb 12;82(4):359-61. doi: 10.1002/(sici)1096-8628(19990212)82:43.0.co;2-q. No abstract available.
- Background: PubMed 10521845Balci S, Altinok G, Ozaltin F, Aktas D, Niron EA, Onol B. Laryngeal atresia presenting as fetal ascites, olygohydramnios and lung appearance mimicking cystic adenomatoid malformation in a 25-week-old fetus with Fraser syndrome. Prenat Diagn. 1999 Sep;19(9):856-58. doi: 10.1002/(sici)1097-0223(199909)19:93.0.co;2-x.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fraser Syndrome and Fryns Syndrome, run by National Human Genome Research Institute (NHGRI) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00032877, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2008.